2019 Symposium

2018 Symposium

2017 Symposium

2016 Symposium

2015 Symposium

2014 Symposium

2013 Symposium

Previous Symposia

2014 Featured Talks » Zeroing in an oncogenic driver: The Rapid Evolution of Targeted Therapies for Anaplastic Lymphoma Kinase-Positive Lung Cancer

Valeria Fantin from MCC Industry Relations on Vimeo.

Valeria Fantin, PhD
Vice President, Tumor Cell Biology
Pfizer Inc.

Valeria Fantin is currently Vice President of Tumor Cell Biology at Pfizer. She received her PhD in Molecular and Cellular Biology from Dartmouth, where she worked on insulin and IGF1 signaling. She went on to do her postdoctoral training in the department of Genetics at Harvard Medical School. The focus on her research work was breast cancer, and in particular in oncogene-driven metabolic rewiring. Prior to joining Pfizer, Valeria held positions at Merck, Ariad Pharmaceuticals and Agios Pharmaceuticals leading target validation as well as drug discovery and development projects in diverse areas including signal transduction, epigenetics and cancer metabolism.